In this study, DD-9 has been shown as a potential candidate against hepatocellular and cervical cancer by downregulating the transcription level of β-catenin-stimulated Wnt target gene and the expression of related proteins including p-GSK3-β, β-catenin, LEF1, c-Myc, and CyclinD1; and by upregulating GSK3-β expression, which indicates that DD-9 stabilized the β-catenin degradation complex, thereby inducing β-catenin degradation and inactivation of the Wnt/β-catenin pathway. This evidence concerns the gene MYC and cervical carcinoma.